Literature DB >> 8241046

Arcuate keratotomy for the correction of spherical hyperopia in human cadaver eyes.

M P Vrabec1, D S Durrie, J D Hunkeler.   

Abstract

BACKGROUND: A new experimental surgical technique to correct spherical hyperopia by steepening of the central corneal curvature was performed on human cadaver eyes.
METHODS: Ten eyes were used in the study. All were pretreated with glycerin to ensure a uniform corneal thickness between .55 and .65 mm on ultrasonic pachometry. A constant intraocular pressure of approximately 30 to 40 mm Hg was maintained in each eye by the injection of saline into the vitreous cavity. This was verified by pneumotonometry. A vertical blade diamond knife was set at 100% of the thinnest of four paracentral readings. Each eye underwent preoperative computed topography. One set of five eyes had 12 incisions made following a 5.75-millimeter diameter Mendez hexagonal marker that included unconnected T incisions at each junction (ie, "Hex T" pattern). The other set of five eyes had four arcuate incisions made following a 6-millimeter diameter zone marker; each incision was 60 degrees in arc. Immediately after surgery, computed topography was repeated.
RESULTS: The hexagonal keratotomy set of eyes had an average steepening of the cornea of 0.80 D with a range of -1.05 to + 4.38 D. The arcuate keratotomy set had an average steepening of +2.12 D with a range of +1.27 to +3.27 D.
CONCLUSIONS: This study suggests arcuate keratotomy may be a more effective procedure in the correction of spherical hyperopia when compared with hexagonal keratotomy. The amount of corneal steepening achieved in a cadaver eye model may not be the same as when performed in vivo.

Entities:  

Mesh:

Year:  1993        PMID: 8241046

Source DB:  PubMed          Journal:  Refract Corneal Surg        ISSN: 1042-962X


  1 in total

1.  The surgical correction of moderate hypermetropia: the management controversy.

Authors:  C N McGhee; S Ormonde; T Kohnen; M Lawless; A Brahma; I Comaish
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.